Financial Times - July 22



July 22 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Headlines

- Pfizer and Flynn fined 70 mln stg by UK regulator for epilepsy drug price rises Link

- EDF pushes UK government to alter Hinkley Point C penalty clauses Link

- Tata threatens to close Port Talbot steelworks without 1.5 bln stg of aid Link

- Marks and Spencer finance chief to depart retailer and join Primark owner ABF Link

Overview

- Pfizer PFE.N and Flynn Pharma were fined 70 million pounds ($83.90 million) on Thursday by Britain's antitrust watchdog for overcharging the National Health Services (NHS) for a life-saving epilepsy drug.

- France's EDF EDF.PA is pushing the UK government to alter a key subsidy contract to avoid missing out on billions of pounds in guaranteed revenue after the Covid-19 pandemic caused further delays to Hinkley Point C, the first new nuclear power station under construction in the UK in almost 30 years.

- India-based Tata Group TISC.NS , has threatened to shut down operations if the UK government does not agree in the next year to provide 1.5 billion pounds ($1.80 billion) of subsidies to help it reduce carbon emissions.

- Marks & Spencer MKS.L said finance and strategy chief Eoin Tonge would leave the British clothing and food retailer to take up a role at Associated British Foods (ABF) ABF.L , owner of budget fashion chain Primark.

($1 = 0.8343 pounds) (Compiled by Bengaluru newsroom)

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.